https://scholars.lib.ntu.edu.tw/handle/123456789/582201
標題: | Changes of soluble CD26 and CD30 levels correlate with response to interferon plus ribavirin therapy in patients with chronic hepatitis C | 作者: | Yang S.-S. Fu L.-S. Chang C.-S. Yeh H.-Z. Chen G.-H. JIA-HORNG KAO |
關鍵字: | Chronic hepatitis; Hepatitis C virus; Interferon; Lymphocytes; Ribavirin; sCD26; sCD30; Th1/Th2 response | 公開日期: | 2006 | 出版社: | Blackwell Publishing | 卷: | 21 | 期: | 12 | 起(迄)頁: | 1789-1793 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Background: Clearance of hepatitis C virus (HCV) is attributed to host cellular immune responses, in which T helper cells play a critical role. The purpose of the present paper was therefore to study the serial changes of serum soluble markers released from T helper 1 (Th1) and 2 (Th2) and their correlations with treatment responses in chronic hepatitis C patients receiving interferon-α plus ribavirin for 24 weeks. Methods: Serum markers (soluble CD26 and CD30 levels) of T helper cells were quantified before and 6 months after combination therapy in 33 chronic hepatitis C patients and in 20 healthy controls. Results: Compared to healthy controls, chronic hepatitis C patients had significantly lower serum soluble CD26 levels before (140.4 ± 63.9 ng/mL vs 200.6 ± 60.3 ng/mL, P < 0.0001) and after (115.9 ± 32.9 ng/mL vs 200.6 ± 60.3 ng/mL, P < 0.0001) combination therapy. The level was even lower in those with non-sustained virologic response (non-SVR; 139.0 ± 50.9 ng/mL vs 117.7 ± 40.3 ng/mL, P = 0.039). In contrast, soluble CD30 levels at 6 months after combination therapy were significantly lower in patients with SVR than those with non-SVR (6.4 ± 3.5 U/mL vs 10.4 ± 5.4 U/mL, P = 0.021). Conclusion: Chronic hepatitis C patients have a weak Th1 response as reflected by lower soluble CD26 levels and the levels are even lower in non-sustained responders. In sharp contrast, downregulation of Th2 response with serial changes of soluble CD30 level is associated with successful treatment of HCV infection. ? 2006 The Authors. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33750452743&doi=10.1111%2fj.1440-1746.2006.04677.x&partnerID=40&md5=31dbd4bf36ad604b3e9a2ec3d27cc10b https://scholars.lib.ntu.edu.tw/handle/123456789/582201 |
ISSN: | 0815-9319 | DOI: | 10.1111/j.1440-1746.2006.04677.x | SDG/關鍵字: | alpha2b interferon; CD30 antigen; dipeptidyl peptidase IV; interferon; peginterferon; ribavirin; article; cellular immunity; clinical article; controlled study; drug dose regimen; drug response; genotype; helper cell; hepatitis C; host cell; human; immune response; priority journal; treatment response; virology |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。